全文获取类型
收费全文 | 452篇 |
免费 | 8篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 23篇 |
妇产科学 | 5篇 |
基础医学 | 14篇 |
口腔科学 | 2篇 |
临床医学 | 103篇 |
内科学 | 139篇 |
皮肤病学 | 17篇 |
神经病学 | 29篇 |
特种医学 | 2篇 |
外科学 | 51篇 |
综合类 | 7篇 |
一般理论 | 1篇 |
预防医学 | 20篇 |
药学 | 30篇 |
肿瘤学 | 19篇 |
出版年
2024年 | 1篇 |
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 16篇 |
2012年 | 21篇 |
2011年 | 29篇 |
2010年 | 13篇 |
2009年 | 28篇 |
2008年 | 15篇 |
2007年 | 23篇 |
2006年 | 36篇 |
2005年 | 16篇 |
2004年 | 10篇 |
2003年 | 6篇 |
2002年 | 8篇 |
2001年 | 24篇 |
2000年 | 14篇 |
1999年 | 19篇 |
1998年 | 25篇 |
1997年 | 15篇 |
1996年 | 22篇 |
1995年 | 13篇 |
1994年 | 18篇 |
1993年 | 12篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1963年 | 2篇 |
1959年 | 2篇 |
排序方式: 共有463条查询结果,搜索用时 31 毫秒
91.
CHRONIC SACRAL NEUROMODULATION IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS: RESULTS FROM A NATIONAL REGISTER 总被引:5,自引:0,他引:5
M. SPINELLI P. BERTAPELLE F. CAPPELLANO A. ZANOLLO R. CARONE F. CATANZARO G. GIARDIELLO F. DE SETA ON BEHALF OF THE GINS GROUP 《The Journal of urology》2001,166(2):541-545
PURPOSE: The Italian Register was created in February 1997 to collect the national results of sacral neuromodulation. All Italian centers at which sacral neuromodulation is performed were invited to participate in our study. We present the results from retrospective and prospective registers. MATERIALS AND METHODS: A total of 196 patients underwent permanent implantation of sacral neuromodulation and were enrolled in the Italian register. There were 18 males and 75 females in the retrospective, and 28 males and 75 females in the prospective studies. Student's t test was used to compare paired values, and the Wilcoxon rank sum and nonparametric tests were used when necessary. RESULTS: Mean incontinent episodes daily plus or minus standard deviation for patients with detrusor instability went from 5.4 +/- 3.9 to 1.1 +/- 1.6 (median 5 and 0, respectively) at 12-month followup (p <0.001). For idiopathic retention average residual volume decreased from 277 to 108 cc (median 287 and 80, respectively), and 50% of patients stopped catheterization and another 13% catheterized once daily at 1-year after implantation. With neurogenic voiding disturbances, the results fluctuated with time from a minimum of 33% to a maximum 66% of patients who did not catheterize at 6-month followup and 12 months after implantation, respectively. At 12-month followup, 50% of patients with hyperreflexia had less than 1 incontinent episode daily. The problem was completely solved in 66% of patients in the retention group. Of patients in the urge incontinent population 39% were completely dry and 23% had less than 1 incontinent episode daily. CONCLUSIONS: Sacral neuromodulation is effective therapy for treating lower urinary tract symptoms resistant to less invasive therapy. 相似文献
92.
F. BERNARDI A. DOLCE† M. PINOTTI A. D. SHAPIRO‡ E. SANTAGOSTINO§ F. PEYVANDI§ A. BATOROVA¶ M. LAPECORELLA J. F. SCHVED†† J. INGERSLEV‡‡ G. MARIANI FOR THE INTERNATIONAL FACTOR VII DEFICIENCY STUDY GROUP 《Journal of thrombosis and haemostasis》2009,7(5):774-779
Summary. Background: The autosomally-inherited factor VII (FVII) deficiency and X-linked hemophilia B offer an attractive model to investigate whether reduced levels of FVII and FIX, acting in the initiation and amplification of coagulation respectively, influence hemostasis to a different extent in relation to age and bleeding site. Methods: Hemophilia B patients ( n = 296) and FVII-deficient males ( n = 109) were compared for FVII/FIX clotting activity, F7/F9 genotypes and clinical phenotypes in a retrospective, multi-centre, cohort study. Results: Major clinical differences between diseases were observed. Bleeding occurred earlier in hemophilia B (median age 2.0 years, IR 0.9–5.0) than in FVII deficiency (5.2 years, IR 1.9–15.5) and the bleeding-free survival in FVII deficiency was similar to that observed in 'mild' hemophilia B ( P = 0.96). The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding). Differences were confirmed by analysis of FVII-deficient women. Conclusions: Our data support the notion that low FVII levels sustain hemostasis better than similarly reduced FIX levels. On the other hand, minute amounts of FVII, differently to FIX, are needed to prevent fatal bleeding, as indicated by the rarity of null mutations and the associated life-threatening symptoms in FVII deficiency, which contributes towards shaping clinical differences between diseases in the lowest factor level range. Differences between diseases are only partially explained by mutational patterns and could pertain to the specific roles of FVII and FIX in coagulation phases and to vascular bed-specific components. 相似文献
93.
A. COPPOLA M. MARGAGLIONE†‡ E. SANTAGOSTINO§ A. ROCINO¶ E. GRANDONE‡ P. M. MANNUCCI§ G. DI MINNO FOR THE AICE PROFIT STUDY GROUP 《Journal of thrombosis and haemostasis》2009,7(11):1809-1815
Summary. Background: Immune tolerance induction (ITI) is the only therapeutic approach that can eradicate factor VIII (FVIII) inhibitors in patients with hemophilia A. Predictors of ITI outcome are still debated, and the role of F8 gene mutations in this is not well established. Objectives: To investigate the relationship between F8 genotype and ITI outcome in patients with severe hemophilia A and high‐responding inhibitors. Patients and Methods:F8 mutations were identified in 86 patients recruited as part of the Italian ITI registry (the PROFIT study). ITI outcome was centrally reviewed according to the following definitions: success (undetectable inhibitor and normal FVIII pharmacokinetics), partial success (inhibitor titer < 5 BU mL?1 and/or abnormal FVIII pharmacokinetics), and failure. Results:F8 mutations known to be associated with a high risk of inhibitor development (large deletions, inversions, nonsense mutations and splice site mutations) were found in 70 patients (81%); among these, the intron 22 inversion was present in 49 patients (57%). In 16 patients (19%) lower‐risk F8 defects (small insertions/deletions and missense mutations) were identified. The latter group of patients showed a significantly higher ITI success rate than those carrying high‐risk mutations [13/16 (81%) vs. 33/70 (47%); risk ratio 1.7, 95% confidence interval (CI) 1.1–2.1, P = 0.01]. On multivariate analysis, the mutation risk class remained a significant predictor of success [adjusted odds ratio (OR) 6.2, 95% CI 1.1–36.0, P = 0.04], as were inhibitor titer at ITI start (< 5 BU mL?1, OR 11.8, 95% CI 3.5–40.2, P < 0.001), and peak titer during ITI (< 100 BU mL?1, OR 11.4, 95% CI 3.2–40.8, P < 0.001). Conclusions: ITI success is influenced by F8 genotype. This knowledge should contribute to the stratification of prognosis, and to the clinical choices made for ITI in patients with high‐responding inhibitors. 相似文献
94.
95.
Enrolment and baseline characteristics in the WHO Multicentre Growth Reference Study 总被引:1,自引:0,他引:1
WHO MULTICENTRE GROWTH REFERENCE STUDY GROUP & Mercedes de Onis 《Acta paediatrica (Oslo, Norway : 1992)》2006,95(S450):7-15
Aim: To describe the WHO Multicentre Growth Reference Study (MGRS) sample with regard to screening, recruitment, compliance, sample retention and baseline characteristics.
Methods: A multi-country community-based study combining a longitudinal follow-up from birth to 24 mo with a cross-sectional survey of children aged 18 to 71 mo. Study subpopulations had to have socio-economic conditions favourable to growth, low mobility and ≥ 20% of mothers practising breastfeeding. Individual inclusion criteria were no known environmental constraints on growth, adherence to MGRS feeding recommendations, no maternal smoking, single term birth and no significant morbidity. For the longitudinal sample, mothers and newborns were screened and enrolled at birth and visited 21 times at home until age 24 mo.
Results: About 83% of 13 741 subjects screened for the longitudinal component were ineligible and 5% refused to participate. Low socio-economic status was the predominant reason for ineligibility in Brazil, Ghana, India and Oman, while parental refusal was the main reason for non-participation in Norway and USA. Overall, 88.5% of enrolled subjects completed the 24-mo follow-up, and 51% (888) complied with the MGRS feeding and no-smoking criteria. For the cross-sectional component, 69% of 21 510 subjects screened were excluded for similar reasons as for the longitudinal component. Although low birthweight was not an exclusion criterion, its prevalence was low (2.1% and 3.2% in the longitudinal and cross-sectional samples, respectively). Parental education was high, between 14 and 15 y of education on average.
Conclusion: The MGRS criteria were effective in selecting healthy children with comparable affluent backgrounds across sites and similar characteristics between longitudinal and cross-sectional samples within sites. 相似文献
Methods: A multi-country community-based study combining a longitudinal follow-up from birth to 24 mo with a cross-sectional survey of children aged 18 to 71 mo. Study subpopulations had to have socio-economic conditions favourable to growth, low mobility and ≥ 20% of mothers practising breastfeeding. Individual inclusion criteria were no known environmental constraints on growth, adherence to MGRS feeding recommendations, no maternal smoking, single term birth and no significant morbidity. For the longitudinal sample, mothers and newborns were screened and enrolled at birth and visited 21 times at home until age 24 mo.
Results: About 83% of 13 741 subjects screened for the longitudinal component were ineligible and 5% refused to participate. Low socio-economic status was the predominant reason for ineligibility in Brazil, Ghana, India and Oman, while parental refusal was the main reason for non-participation in Norway and USA. Overall, 88.5% of enrolled subjects completed the 24-mo follow-up, and 51% (888) complied with the MGRS feeding and no-smoking criteria. For the cross-sectional component, 69% of 21 510 subjects screened were excluded for similar reasons as for the longitudinal component. Although low birthweight was not an exclusion criterion, its prevalence was low (2.1% and 3.2% in the longitudinal and cross-sectional samples, respectively). Parental education was high, between 14 and 15 y of education on average.
Conclusion: The MGRS criteria were effective in selecting healthy children with comparable affluent backgrounds across sites and similar characteristics between longitudinal and cross-sectional samples within sites. 相似文献
96.
Infections with Nonthoracotomy Implantable Cardioverter Defibrillators: Can These Be Prevented? 总被引:3,自引:0,他引:3
PETER N. SMITH HUMBERTO J. VIDAILLET JOHN J. HAYES PATRICK J. WETHINGTON LYNNETT STAHL MICHAEL HULL STEVEN K. BROSTE for the ENDOTAK LEAD CLINICAL INVESTIGATORS 《Pacing and clinical electrophysiology : PACE》1998,21(1):42-55
Nonthoracotomy ICDs are believed to be the best therapeutic modality for treatment of life-threatening ventricular arrhythmias. Little is known about the risk of infection with initial implantation of these devices. We studied the incidence, clinical characteristics, and risk factors associated with infections in 1,831 patients with nonthoracotomy ICD from the Endotak-C nonthoracotomy lead registry of Cardiac Pacemakers, Inc. A transvenous lead was implanted in 950 patients (51.9%) and a combination transvenous plus subcutaneous patch was used in 881 patients (48.1%). Nine preselected data variables were studied, and all investigators identified as having patients with infections were personally contacted. Infections occurred in 22 (1.2%) of 1,831 patients receiving this nonthoracotomy ICD system. The mean time to infection was 5.7 ± 6.5 months (range 1–25 months). Staphylococci were isolated in 58% of patients with reported infection. The presence of a subcutaneous defibrillator patch system was associated with the development of infection. Six of 950 patients (0.63%) with a totally transvenous lead system developed infection versus 16 of 838 (1.9%) patients with a transvenous lead plus subcutaneous patch system configuration (P = 0.015, Chi-square test), with an unadjusted estimated odds ratio of 3.06 (CI 1.19–7.86). The risk of infection encountered with the nonthoracotomy ICD is low, estimated from our data to be 1.2%. Placement of a subcutaneous defibrillator patch appears to be an independent risk factor for development of infection. 相似文献
97.
A. Yoshioka M. Shima K. Fukutake J. Takamatsu & A. Shirahata the KOGENATE FS STUDY GROUP 《Haemophilia》2001,7(3):242-249
The recombinant full-length FVIII product Kogenate has been reformulated using sucrose (rFVIII-FS) instead of human serum albumin as a stabiliser in purification and formulation. The in vivo recovery, haemostatic efficacy, and safety of rFVIII-FS were investigated in 20 previously treated patients with severe or moderate haemophilia A for > or = 24 weeks. In vivo recoveries of 73.5 +/- 16.3%, 78.4 +/- 16.1%, and 82.8 +/- 23.9% after the initial infusion of 50 IU kg(-1) rFVIII-FS and at weeks 12 and 24, respectively, showed no significant changes over time. A total of 1115 infusions (mean dose 24.1 +/- 8.4 IU kg(-1)) were included in the analysis of haemostatic efficacy. One (80.5%) or two (8.2%) infusions achieved adequate haemostasis in 88.7% of all bleeding episodes, and haemostatic efficacy was judged 'excellent' or 'good' in 749 of 764 episodes (98.0%). The haemostatic efficacy was judged as 'excellent' or 'good' in 924 of 1115 (82.9%) infusions. Twenty-one adverse events were observed in 12 patients in the total 1541 infusions included in the safety analysis. Causality with respect to rFVIII-FS could not be ruled out in three events in one HIV-negative patient: elevated CD4(%), decreased CD8(%), and elevated CD4/CD8 ratio. No FVIII inhibitor development was observed in any patient. ELISA assay testing for antibodies to rFVIII, baby hamster kidney cell (BHK) protein, and murine IgG were all negative. These results show that rFVIII-FS is a safe and effective for long-term treatment of patients with haemophilia A. 相似文献
98.
99.
KOICHI NAGAO NOBUHISA ISHII SADAO KAMIDONO TAKAO OSADA THE VARDENAFIL CLINICAL TRIAL GROUP 《International journal of urology》2004,11(7):515-524
AIM: Vardenafil is a selective and highly potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), with improved selectivity for PDE5 and demonstrated efficacy for improving sexual function in men with ED. The current study investigated the safety and efficacy of this new PDE5 inhibitor in Japanese men with ED. METHODS: This was a prospective, double blind, randomized clinical trial designed to evaluate the efficacy and safety of vardenafil. Following a 4-week treatment-free observation period, 283 eligible patients were randomized to 12 weeks treatment with vardenafil 5 mg, 10 mg, 20 mg, or placebo. Primary efficacy responses were assessed using the scores of Q3 and Q4 of the international index of erectile function (IIEF). RESULTS: All three vardenafil doses showed significantly better improvement than the placebo group in Q3 and Q4 scores of the IIEF questionnaire, either at 12 weeks or at the 'last observation carried forward' (LOCF, P < 0.0001). Q3 scores were improved to 4.06 with vardenafil 5 mg, 4.53 with vardenafil 10 mg, and 4.64 with vardenafil 20 mg, versus 3.17 with placebo. Comparable scores for Q4 were 3.47, 4.15 and 4.31 versus 2.31 for placebo. Up to 86% of patients achieved improved erections as assessed by the global assessment question (GAQ). Reported adverse event rates were 35.3%, 45.3% and 54.5% with vardenafil 5 mg, 10 mg and 20 mg, respectively, versus 21.1% in the placebo group. No serious adverse drug reactions were reported. The most common treatment-emergent adverse events were transient headache, flushing and rhinitis, which were mostly mild. CONCLUSION: Vardenafil is an effective and well-tolerated treatment for ED and provides improvement in key indices of erectile function among Japanese men with ED. The results of our trial show that up to nearly 90% of patients achieve improved erections with the administration of vardenafil. 相似文献
100.
COHEN-SOLAL A.; AUPETIT J. F.; GUERET P.; KOLSKY H.; F ZANNAD ON BEHALF OF THE Vo FRENCH STUDY GROUP 《European heart journal》1994,15(2):236-241
Anaerobic threshold (AT), proposed as a non-invasiveindex of exercise tolerance, independent of patient motivation,is considered more reliable than exercise duration in assessingthe effect of drug therapy in chronic heart failure (CHF). However,inter-observer variation in patients may be more difficult thanin normal subjects. In a multicentre study, 85 patients from10 centres performed a total of 331 bicycle maximal tests (rampprotocols, 10 watts. min1) with respiratory gas analysisby different systems. A central committee reviewed all the tests.Percentages of AT determination ranged from 34% to 71% dependingon the method used. Apart from the respiratory exchange ratio(RER=1) method, which yielded the lowest rate of determination.and the crossing point (when RER=1), which yielded the highestrate, 71%, other methods of determination, such as carbon dioxide(42%), minute ventilation (52%) or ventilatory equivalents plottedvs time (57%), did not dtffer in the rate of AT determination. Thus, even among trained physicians, AT determination was notreliable. The crossing point may nevertheless be a valuableindex from a pragmatic standpoint, although it occurs afterthe actual AT Peak oxygen uptake should remain the main end-pointin assessment of exercise capacity. 相似文献